Maharashtra FDA Cancels 10 Ayurvedic Drug Licences

The Maharashtra Food and Drug Administration (FDA) has launched a statewide crackdown on Ayurvedic drug manufacturers after inspections found serious violations of prescribed manufacturing and quality-control standards at several establishments.

The Maharashtra FDA inspected 434 Ayurvedic drug manufacturers statewide and issued 135 show-cause notices for violations. The inspections were carried out to assess compliance with the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and Schedule T, which lays down Good Manufacturing Practices (GMP) requirements for Ayurvedic, Siddha and Unani medicines.

The FDA found several instances of non-compliance, including the absence of qualified or approved technical personnel, non-functional quality-control departments, and lack of machinery and equipment required for manufacturing and testing. Several establishments were also found to have unhygienic manufacturing premises, missing or discrepant batch production records and raw-material records, and incorrect manufacturing dates on product labels.

In the most serious cases, the FDA has permanently cancelled the manufacturing licences of 10 Ayurvedic drug manufacturers after finding major violations that could affect the quality, safety and efficacy of medicines and pose a public health concern. The FDA has warned manufacturers to strictly follow GMP and face stringent action if they fail to comply.

The inspections also revealed that some establishments had no records of training provided to technical employees and lacked Control Samples and Master Formula Records, which are important components of pharmaceutical quality control. The FDA also found inadequate procedures to prevent cross-contamination during the manufacturing process.

The crackdown on Ayurvedic drug manufacturers is part of the FDA's efforts to ensure that medicines manufactured in the state are safe and effective for consumption. The FDA has directed the establishments that were issued show-cause notices to explain the violations detected during inspections and comply with the prescribed requirements.

The cancellation of licences of 10 Ayurvedic drug manufacturers is a significant step towards ensuring the quality and safety of medicines in Maharashtra. The FDA's actions are expected to have a positive impact on the health and wellbeing of consumers in the state.

The Maharashtra FDA's crackdown on Ayurvedic drug manufacturers is also a reminder of the importance of regulatory compliance in the pharmaceutical industry. Manufacturers must ensure that they follow the prescribed standards and guidelines to avoid action from regulatory authorities.

In conclusion, the Maharashtra FDA's crackdown on Ayurvedic drug manufacturers is a welcome step towards ensuring the quality and safety of medicines in the state. The FDA's actions are expected to have a positive impact on the health and wellbeing of consumers in Maharashtra and serve as a reminder of the importance of regulatory compliance in the pharmaceutical industry.